Teva Is Committed To Alvotech Alliance – But Would ‘Love’ To Move On Adalimumab ‘Soon’

‘We Really Think We Could Do A Great Job With That,’ Says Teva CEO Francis

Teva has spoken of its US biosimilars alliance with Alvotech, in the wake of several major setbacks for the companies’ plans to launch a biosimilar to AbbVie’s Humira (adalimumab) juggernaut on 1 July.

hands of love_298731920
• Source: Shutterstock

Alvotech was left reeling last month after being denied US approval for its AVT02 proposed high-concentration biosimilar to Humira (adalimumab), with the clock ticking on its prospective 1 July allowed entry date into the market.

The US Food and Drug Administration blocked approval for the biosimilar by issuing a complete response letter over deficiencies at...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.